Anagenics Limited · ASX:AN1

Anagenics — Cellmid — FY2017 Earnings Presentation

29 slides from Anagenics's earnings presentation, Sep 27, 2017

  1. Slide 1: ASX Announcement: Cellmid's FY2017 Results Presentation

    Slide 1: ASX Announcement: Cellmid's FY2017 Results Presentation

    ASX ANNOUNCEMENT CELLMID’S FY2017 RESULTS PRESENTATION SYDNEY: Wednesday, 27 September 2017, Cellmid Limited (ASX: CDY) is pleased to provide shareholders with the following presentation on the results of the 2017 financial year. In consumer health news, revenues for wholly owned subsidiary, Advange

  2. Slide 2: Cellmid Limited September 2017

    Slide 2: Cellmid Limited September 2017

    CELLMID LIMITED SEPTEMBER 2017 Maria Halasz CEO & Managing Director @mariahalasz

  3. Slide 3: Important Notice

    Slide 3: Important Notice

    IMPORTANT NOTICE Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the

  4. Slide 4: Cellmid (CDY:ASX)

    Slide 4: Cellmid (CDY:ASX)

    CELLMID (CDY:ASX) Fully Paid Ordinary Shares (1 September 2017) 1,068,456,303 Market Capitalisation (1 September 2017) A$ 27 million 32,500,000 Unlisted options (executive) Cash Position (30 June 2017) A$ 4 million Debt ($2 million due Feb 2019, secured against R&D Tax Credit) A$ 2.0 million

  5. Slide 5: Corporate and Business Structure

    Slide 5: Corporate and Business Structure

    CORPORATE AND BUSINESS STRUCTURE LYRAMID KINERA Novel FGF5 inhibitor hair Midkine antibodies for the Midkine protein for the growth products sold as treatment of fibrosis, treatment of post- OTC, non-prescription chronic kidney disease ischemic conditions natural medicines and and cancer conditions

  6. Slide 6: Board Members

    Slide 6: Board Members

    BOARD MEMBERS Dr David King | Chairman Bruce Gordon | Non-Executive Director An experienced independent chairman with expertise in Bruce is a seasoned audit partner and corporate finance high growth companies, David has a track record in specialist with over 35 years’ industry experience. Bruce buil

  7. Slide 7: Financial Performance

    Slide 7: Financial Performance

    FINANCIAL PERFORMANCE Financial Results 2014-2017 2014 2015 2016 2017 Total revenue and other income $ 1,898,037 $ 2,930,518 $ 4,611,108 $ 5,560,121 Consumer health revenue $ 1,150,931 $ 1,842,804 $ 2,962,306 $ 4,453,208 Midkine license revenue $ 1,009,188 $ 99,263 $ 205,390 $ 247,606 R&D tax credit

  8. Slide 8: Consumer Health Revenue 2014 – 2017

    Slide 8: Consumer Health Revenue 2014 – 2017

    CONSUMER HEATH REVENUE 2014 – 2017 Consumer Health Revenue Consumer health revenue up by: 286.9% from 2014 50.3% from 2016 2014 2015 2016 2017

  9. Slide 9: Total Revenue 2014 – 2017

    Slide 9: Total Revenue 2014 – 2017

    TOTAL REVENUE 2014 – 2017 Total Revenue Total revenue up by: 192.9% from 2014 20.6% from 2016 2014 2015 2016 2017

  10. Slide 10: Advangen in FY2017

    Slide 10: Advangen in FY2017

    ADVANGEN in FY2017 • Signed distribution partnership in the US in July 2016 • Increased revenue by 50% in existing markets • Developed the global brand • Completed manufacture and launched in the US • Secured first retail partnership with Neiman Marcus • Received import permits to China

  11. Slide 11: Lyramid Limited in FY2017

    Slide 11: Lyramid Limited in FY2017

    LYRAMID Limited in FY2017 • Nature publication showing that midkine has a crucial role in driving metastasis in melanoma • Pre-clinical validation programs continued in animal models of chronic kidney disease and systemic complications • Pre-clinical validation programs planned in animal models of c

  12. Slide 12: Kinera Limited in FY2017

    Slide 12: Kinera Limited in FY2017

    KINERA Limited in FY2017 • Preclinical validation of MK in chronic heart failure continued during FY2017 • GMP manufacture of MK commenced in preparation for IND-enabling studies • Preclinical studies in brain ischemia planned and partners identified

  13. Slide 13: évolis scalp lotion products

    Slide 13: évolis scalp lotion products

    Jo-Ju Léxilis évolis évolis SCALP LOTION SCALP LOTION PROFESSIONAL No More Bad Hair Days (advangen advanced gene science for hair “ay

  14. Slide 14: FGF5 publications reference

    Slide 14: FGF5 publications reference

    *Publications on FGF5 are available via the évolis® website, www.evolisproducts.com.au/scientific-publications

  15. Slide 15: Our Hair

    Slide 15: Our Hair

    d how we feel. Hair is the root of our s ea good hair day have a great day.

  16. Slide 16: $11.6 billion 180 million

    Slide 16: $11.6 billion 180 million

    40% $11.6 billion 50% 180 million ‡ ‡ derived from US Census data 2010

  17. Slide 17: Hair Opportunity

    Slide 17: Hair Opportunity

    Hair Opportunity

  18. Slide 18: What Makes Us Different?

    Slide 18: What Makes Us Different?

    WHAT MAKES US DIFFERENT ? HAIR CARE LINE CREATED BY HAIR BIOLOGISTS TO DELIVER YOUR BEST HAIR FORMULATED WITH ACOMPLETE REAL WORKING PORTFOLIO TO 100% NATURAL RESOLVE A SPECTRUM ACTIVES OF HAIR CHALLENGES évolis PROFESSIONAL REAL RESULTS BACKED BY SCIENCE

  19. Slide 19: Hair growth cycle and FGF5

    Slide 19: Hair growth cycle and FGF5

    aN THE i ‘ ANAGEN : PHASE HAIR GROWTH IS) I \; \ Rui. Ba BY FGEF5 THE Ty WHAT IS FGF5: Anaturally occurring protein inthe CATAGEN $calp that controls the hairlife cycle. Stress, PHASE \ \ © genetics and environmental factors can cause an imbalance in the hair life cycle. By controlling FGFS the hair

  20. Slide 20: Effects of FGF5 and inhibiting FGF5

    Slide 20: Effects of FGF5 and inhibiting FGF5

    NEGATIVE EFFECTS Of FGF5 WHEN YOU INHIBIT FGF5 évolis® évolis®

  21. Slide 21: Common hair challenges and botanical actives

    Slide 21: Common hair challenges and botanical actives

    COMMON HAIR CHALLENGES With the botanical actives in évolis® évolis® évolis®

  22. Slide 22: Beauty Found in Nature

    Slide 22: Beauty Found in Nature

    Beauty Found in Nature

  23. Slide 23: Results of Blinded Placebo Controlled Clinical Study

    Slide 23: Results of Blinded Placebo Controlled Clinical Study

    RESULTS OF BLINDED PLACEBO controlled Clinical STUDY 20% 44% 82% *20 faster hair growth was observed in users at 4 months. Double blinded placebo controlled study, Department of Dermatological Science, The University of Tokushima Japan (2007, Maeda et al). + The botanical actives in ‘evolis® (includ

  24. Slide 24: Results of Consumer Usage Study

    Slide 24: Results of Consumer Usage Study

    RESULTS OF CONSUMER USAGE STUDY 100% 97% 96% 87% Of users experienced Of users experienced Of users saw an Of users improved their new hair growth less hair fall improvement in hair position on the texture Norwood/Ludwig Scales 30 days 60 days 90 days 120 days Never + In a 2017 Consumer Usage Study

  25. Slide 25: Real Users. Real Results.

    Slide 25: Real Users. Real Results.

    CONTROL THINNING HAIR LOSS TEXTURE Day 120 Day 120

  26. Slide 26: Big Plans for Hair

    Slide 26: Big Plans for Hair

    BIG PLANS FOR HAIR Looking into the future New Products to support GREAT hair

  27. Slide 27: New products: Revive & Lift, Style & Magnify, Lash Creator, Brow Generator

    Slide 27: New products: Revive & Lift, Style & Magnify, Lash Creator, Brow Generator

    Revive & Lift spray Style & Magnifycream Non-comedogenic dry shampoo, Silicone free styling cream tames effortlessly refreshes hair without hair with touchable polymers while clogging hair follicles. magnifying each strands Formulated using special micro- circumference. Hair appears boosters to inst

  28. Slide 28: Summary

    Slide 28: Summary

    SUMMARY • Balanced portfolio of life sciences assets with strong global revenue growth from consumer health expected to continue with entering new markets • Track record of delivering sales growth year on year in the consumer health division • Major potential upside from midkine drug therapeutics (p

  29. Slide 29: Cellmid Limited

    Slide 29: Cellmid Limited

    Cellmid Limited Suite 1802, Level 18, 15 Castlereagh Street Sydney NSW 2000 AUSTRALIA T: +61 2 9221 6830 F: +61 2 9233 8975 www.cellmid.com.au www.evolisproducts.com.au www.evolisprofessional.com.au

Source: Internet Archive copy of anagenics.com

More decks from Anagenics Limited

All 38 Anagenics decks